BIOMARKERS FOR NEUROLOGICAL CONDITIONS

摘要

Low molecular weight (LMW) peptides have been discovered that are indicat ive of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the pr esence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides a re particularly useful in detecting neurological conditions during the early stages without invasive procedures.